GeneDx Holdings (WGS) FCF Margin (2020 - 2026)
GeneDx Holdings (WGS) posted quarterly FCF Margin of 37.48% for Q1 2026, down 4213.0% year-over-year from 0.91% in Q1 2025, and down 491.58% quarter-over-quarter from 9.57% in Q4 2025.
GeneDx Holdings (WGS) FCF Margin (2020 - 2026) Analysis & Trends
GeneDx Holdings (WGS) has reported FCF Margin for 7 consecutive years, with 37.48% the latest figure, recorded in Q1 2026.
- In Q1 2026, FCF Margin fell 4213.0% year-over-year to 37.48%; the TTM figure through Mar 2026 stood at 2.05% (up 103.0% YoY), while the FY2025 annual figure was 7.78%, up 1796.0% from the prior year.
- FCF Margin declined to 37.48% in Q1 2026 per WGS's latest filing, from 9.57% in the prior quarter.
- Across five years, FCF Margin topped out at 9.57% in Q4 2025 and bottomed at 237.81% in Q2 2022.
- Historically, FCF Margin has averaged 60.71% across 5 years, with a median of 37.48% in 2026.
- Annual changes were most pronounced in 2022 — FCF Margin tumbled 17532 bps — and 2023, when it soared 12230 bps.
- GeneDx Holdings' FCF Margin stood at 114.53% in 2022, then soared by 56 bps to 50.11% in 2023, then surged by 93 bps to 3.31% in 2024, then surged by 389 bps to 9.57% in 2025, then tumbled by 492 bps to 37.48% in 2026.
- Business Quant data shows WGS's FCF Margin at 37.48% in Q1 2026, 9.57% in Q4 2025, and 8.22% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.88 Bn | 209.81 Bn | 8.34 Bn | 13.97% |
| 2 | Danaher | 140.65 Bn | 136.30 Bn | 3.61 Bn | 20.19% |
| 3 | Idexx Laboratories | 46.02 Bn | 45.83 Bn | 779.09 Mn | 26.51% |
| 4 | Agilent Technologies | 39.85 Bn | 38.05 Bn | 990.00 Mn | 10.95% |
| 5 | Iqvia Holdings | 39.20 Bn | 37.12 Bn | 1.44 Bn | 8.24% |
| 6 | Natera | 38.80 Bn | 37.70 Bn | 696.04 Mn | 2.59% |
| 7 | Illumina | 30.11 Bn | 28.94 Bn | 770.00 Mn | 13.89% |
| 8 | Mettler Toledo International | 28.66 Bn | 28.61 Bn | 650.22 Mn | 27.51% |
| 9 | Quest Diagnostics | 26.24 Bn | 25.61 Bn | 1.03 Bn | 15.08% |
| 10 | GeneDx Holdings | 2.08 Bn | 1.94 Bn | 78.24 Mn | -34.16% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -34.16% |
| Mar 31, 2026 | -37.48% |
| Dec 31, 2025 | 9.57% |
| Sep 30, 2025 | 8.22% |
| Jun 30, 2025 | 7.84% |
| Mar 31, 2025 | 4.65% |
| Dec 31, 2024 | -3.31% |
| Sep 30, 2024 | -8.46% |
| Jun 30, 2024 | -6.47% |
| Mar 31, 2024 | -27.00% |
| Dec 31, 2023 | -50.11% |
| Sep 30, 2023 | -74.45% |
| Jun 30, 2023 | -115.52% |
| Mar 31, 2023 | -128.79% |
| Dec 31, 2022 | -114.53% |
| Sep 30, 2022 | -104.72% |
| Jun 30, 2022 | -237.81% |
| Mar 31, 2022 | -153.63% |
| Dec 31, 2021 | -76.12% |
| Sep 30, 2021 | -170.30% |